Citing growing demand for emerging microarray applications that complement gene expression studies, Agilent Technologies Inc. (NYSE:A) today announced the extension of its technology access program to National Cancer Institute (NCI) extramural researchers. The NCI funds approximately 4,500 research grants a year.
